U.S. markets open in 3 hours 50 minutes
  • S&P Futures

    3,882.50
    -16.25 (-0.42%)
     
  • Dow Futures

    31,424.00
    -85.00 (-0.27%)
     
  • Nasdaq Futures

    13,218.25
    -61.50 (-0.46%)
     
  • Russell 2000 Futures

    2,255.20
    -19.60 (-0.86%)
     
  • Crude Oil

    60.75
    +0.11 (+0.18%)
     
  • Gold

    1,725.90
    +2.90 (+0.17%)
     
  • Silver

    26.32
    -0.36 (-1.34%)
     
  • EUR/USD

    1.2028
    -0.0032 (-0.26%)
     
  • 10-Yr Bond

    1.4460
    0.0000 (0.00%)
     
  • Vix

    23.53
    -4.42 (-15.81%)
     
  • GBP/USD

    1.3888
    -0.0033 (-0.24%)
     
  • USD/JPY

    106.8670
    +0.1370 (+0.13%)
     
  • BTC-USD

    49,115.64
    +1,816.83 (+3.84%)
     
  • CMC Crypto 200

    988.01
    +1.36 (+0.14%)
     
  • FTSE 100

    6,621.00
    +32.47 (+0.49%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

CytoDyn (CYDY) Completes Enrollment in Phase III COVID-19 Study

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

CytoDyn Inc. CYDY announced that Vyrologix (leronlimab-PRO 140), a CCR5 antagonist, had reached full enrollment in its phase III registrational study for patients with severe-to-critical COVID-19. The 390-patient data will be analyzed in approximately 28 days, with expected results to be announced in mid-January 2021.

However, shares of the company have soared 246% year to date compared with the industry’s growth of 2.5%.

In October 2020, following the review and recommendation by the Data Safety Monitoring Committee (DSMC) of the data from 195 patients, the company continued the study without modification to achieve the primary endpoint. The DSMC also requested a second review of the data after 75% (or 293) of patients were enrolled and completed a 42-day post-enrollment period.  The company concluded it will be far more time efficient to forego the second interim analysis and to analyze the data on 390 patients and to provide final data to the FDA, Health Canada, U.K.’s MHRA, and Philippines FDA, as soon as it is available.

CytoDyn’s phase IIb/IIIstudy will evaluate the efficacy and safety of Vyrologix for patients with severe-to-critical COVID-19 indications. In the study, patients are randomized to receive weekly doses of 700 mg Vyrologix or placebo. Vyrologix and placebo are administered via subcutaneous injection. The primary outcome measured in this study is all-cause mortality at day 28.

Vyrologixis an investigational, humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases and other diseases, including NASH. The FDA has granted a Fast Track designation to Vyrologixfor two potential indications of deadly diseases —one as a combination therapy with HAART for HIV-infected patients and another for metastatic triple-negative breast cancer. 

We also note that CytoDyn completed its phase II study (CD10) of Vyrologixfor COVID-19 in the United States, which produced statistically significant results.

Since the Philippine FDA has relaxed the criteria of Emergency Use Authorization (EUA) for any safe drug with any efficacy data, CytoDyn will file its EUA as soon as the presidential order is implemented by the Philippine FDA.

This month, Pfizer Inc. PFE and BioNTech SE BNTX announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. granted a temporary authorization for emergency use to their mRNA vaccine (BNT162b2) against COVID-19. This marks the first Emergency Use Authorization following a worldwide phase III study of a vaccine to help fight the pandemic. On December 11, the FDA granted emergency use authorization (EUA) to  BNT162b2.

Pharma giant Eli Lilly LLY is also making painstaking efforts to develop several potential neutralizing antibodies for the treatment of COVID-19. In November 2020, Lilly’s antibody therapy bamlanivimab was granted an emergency use authorization by the FDA for treating COVID-19.

CytoDyn currently carries a Zacks Rank #4 (Sell).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

CytoDyn Inc. Price

CytoDyn Inc. Price
CytoDyn Inc. Price

CytoDyn Inc. price | CytoDyn Inc. Quote

Zacks Names “Single Best Pick to Double”

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research SherazMian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
Eli Lilly and Company (LLY) : Free Stock Analysis Report
 
CytoDyn Inc. (CYDY) : Free Stock Analysis Report
 
BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research